<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Nuotio ML</submitter><funding>Sydäntutkimussäätiö</funding><funding>the Finnish Foundation for Cardiovascular Research</funding><funding>Sigrid Jusélius Foundation</funding><pagination>1432-1445</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9586691</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>17(11)</volume><pubmed_abstract>Essential hypertension remains the leading risk factor of global disease burden, but its treatment goals are often not met. We investigated whether DNA methylation is associated with antihypertensive responses to a diuretic, a beta-blocker, a calcium channel blocker or an angiotensin receptor antagonist. In addition, since we previously showed an SNP at the transcription start site (TSS) of the catecholamine biosynthesis-related &lt;i>ACY3&lt;/i> gene to associate with blood pressure (BP) response to beta-blockers, we specifically analysed the association of methylation sites close to the &lt;i>ACY3&lt;/i> TSS with BP responses to beta-blockers. We conducted an epigenome-wide association study between leukocyte DNA methylation and BP responses to antihypertensive monotherapies in two hypertensive Finn</pubmed_abstract><journal>Epigenetics</journal><pubmed_title>Pharmacoepigenetics of hypertension: genome-wide methylation analysis of responsiveness to four classes of antihypertensive drugs using a double-blind crossover study design.</pubmed_title><pmcid>PMC9586691</pmcid><funding_grant_id>08042019KK</funding_grant_id><funding_grant_id>20032019KK</funding_grant_id><pubmed_authors>Sanez Tahtisalo H</pubmed_authors><pubmed_authors>Lahtinen A</pubmed_authors><pubmed_authors>Donner K</pubmed_authors><pubmed_authors>Fyhrquist F</pubmed_authors><pubmed_authors>Kontula KK</pubmed_authors><pubmed_authors>Hiltunen TP</pubmed_authors><pubmed_authors>Nuotio ML</pubmed_authors><pubmed_authors>Perola M</pubmed_authors></additional><is_claimable>false</is_claimable><name>Pharmacoepigenetics of hypertension: genome-wide methylation analysis of responsiveness to four classes of antihypertensive drugs using a double-blind crossover study design.</name><description>Essential hypertension remains the leading risk factor of global disease burden, but its treatment goals are often not met. We investigated whether DNA methylation is associated with antihypertensive responses to a diuretic, a beta-blocker, a calcium channel blocker or an angiotensin receptor antagonist. In addition, since we previously showed an SNP at the transcription start site (TSS) of the catecholamine biosynthesis-related &lt;i>ACY3&lt;/i> gene to associate with blood pressure (BP) response to beta-blockers, we specifically analysed the association of methylation sites close to the &lt;i>ACY3&lt;/i> TSS with BP responses to beta-blockers. We conducted an epigenome-wide association study between leukocyte DNA methylation and BP responses to antihypertensive monotherapies in two hypertensive Finn</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Nov</publication><modification>2026-04-08T11:39:52.645Z</modification><creation>2025-04-19T22:47:03.628Z</creation></dates><accession>S-EPMC9586691</accession><cross_references><pubmed>35213289</pubmed><doi>10.1080/15592294.2022.2038418</doi></cross_references></HashMap>